Pictet Asset Management
LGND icon

Pictet Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Pictet Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$966K Sell
3,055
-57,682
-95% -$13.6M ﹤0.01% 1165
2026
Q1 		$11.7M Sell
60,737
-3,649
-6% -$722K 0.01% 616
2025
Q4 		$12.5M Sell
64,386
-2,582
-4% -$496K 0.01% 625
2025
Q3 		$11.6M Sell
66,968
-2,652
-4% -$394K 0.01% 636
2025
Q2 		$7.95M Sell
69,620
-2,836
-4% -$303K 0.01% 701
2025
Q1 		$7.79M Sell
72,456
-6,670
-8% -$754K 0.01% 716
2024
Q4 		$8.48M Buy
79,126
+1,640
+2% +$185K 0.01% 708
2024
Q3 		$7.55M Buy
77,486
+9,116
+13% +$918K 0.01% 725
2024
Q2 		$5.76M Sell
68,370
-55,675
-45% -$4.43M 0.01% 759
2024
Q1 		$8.96M Sell
124,045
-5,502
-4% -$406K 0.01% 660
2023
Q4 		$9.25M Buy
129,547
+6,744
+5% +$398K 0.01% 659
2023
Q3 		$7.36M Buy
+122,803
New +$8.08M 0.01% 682

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management's LGND Position: Q2 2026 in Review

Pictet Asset Management reduced its Ligand Pharmaceuticals (LGND) stake by 95% in Q2 2026, selling an estimated $13.6M and leaving 3,055 shares worth $966K. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

Pictet Asset Management first reported a position in LGND in Q3 2023 and has held it in 12 quarters since. The position peaked at $12.5M in Q4 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Pictet Asset Management held 3,055 shares of Ligand Pharmaceuticals worth $966K as of Q2 2026.
  • Pictet Asset Management sold 57,682 Ligand Pharmaceuticals shares in Q2 2026, an estimated $13.6M.
  • Ligand Pharmaceuticals made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1165 holding.
  • Pictet Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Ligand Pharmaceuticals position peaked at $12.5M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.